Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel
Philipp
P
Hartmann
Martina
M
Jakob
Andreas
A
Mikesch
Kristina
K
Brink
Ingo
I
Dirnhofer
Stefan
S
Marx
Alexander
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001859:Bone Neoplasms / Q000556:secondary; D018450:Disease Progression; D017809:Fatal Outcome; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008479:Mediastinal Neoplasms / Q000556:secondary; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D017422:Sequence Analysis, DNA; D017384:Sequence Deletion; D013945:Thymoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D013953:Thymus Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit